Insights

Gathering insights about Thermi…

Similar companies to Thermi

Thermi Tech Stack

Thermi uses 8 technology products and services including MySQL, Cart Functionality, Shopify, and more. Explore Thermi's tech stack below.

MySQL
Database
Cart Functionality
E-commerce
Shopify
E-commerce
WooCommerce
E-commerce
jQuery UI
Javascript Libraries
jQuery
Javascript Libraries
Open Graph
Miscellaneous
Vimeo
Video Players

Media & News

ENDO ANNOUNCES CEO TRANSITION
Board to Initiate CEO Search Process; Scott Hirsch Appointed as Interim CEO MALVERN, Pa. , Aug. 27, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company"), a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies, today announced that the Board of Directors has initiated a search for the Company's next Chief Executive Officer and that Blaise Coleman will depart the Company as President & CEO and from the Board of Directors, effective on August 29, 2024.
Aug 27, 2024 | www.prnewswire.com
ENDO REPORTS SECOND-QUARTER 2024 FINANCIAL RESULTS
Raises 2024 Financial Expectations Provides 2025 Financial Expectations MALVERN, Pa. , Aug. 27, 2024 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI), a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies, today reported financial results for the second-quarter ended June 30, 2024[1].
Aug 27, 2024 | www.prnewswire.com
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews - - Separate analysis of patients across MC4R pathway diseases showed one year of treatment with setmelanotide improved NIH, WHO weight classifications - - Previously reported stage one results from Phase 2 DAYBREAK trial showed potential setmelanotide efficacy in multiple MC4R pathway variants; stage two data expected in Q3 2024 - - Preclinical data demonstrated potential of RM-718 to reduce body weight and hunger - - Additional posters feature design of Phase 1 trial of RM-718 and real-world RESTORE study - BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the presentation of the first patient and caregiver reported experiences from qualitative interviews following the completion of a Phase 2 trial that evaluated treatment with setmelanotide in hypothalamic obesity (HO). These results were among six Rhythm presentations at the Endocrine Society Annual Meeting & Expo (ENDO 2024) being held June 1-4 in Boston.
Jun 03, 2024 | www.globenewswire.com
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine
Jun 03, 2024 | www.globenewswire.com
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced it presented a post-hoc analysis from its previously published SONICS study on the effects of levoketoconazole (Recorlev®) in adults with Cushing's syndrome at ENDO 2024 in Boston, June 1-4, 2024. “The results of this analysis suggest that pati.
Jun 03, 2024 | www.businesswire.com
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine disorders with significant unmet medical need, presented results from its Phase 2 POWER study of tildacerfont, a second-generation CRF1 receptor antagonist, for the treatment of polycystic ovary syndrome (PCOS) at the 2024 Annual Meeting of the Endocrine Society (ENDO 2024). “There is a significant u.
Jun 03, 2024 | www.businesswire.com
Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
COPENHAGEN, Denmark, May 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will host informational booths, events, and presentations showcasing use of its innovative TransCon technology in the areas of growth hormone deficiency (GHD), hypoparathyroidism, achondroplasia, and Turner syndrome during ENDO 2024, the annual meeting of the Endocrine Society being held June 1-4, 2024, in Boston.
May 30, 2024 | www.globenewswire.com

Thermi's Email Address Formats

Thermi uses at least 1 format(s):

Thermi Email Formats	Example	Percentage
FLast@thermi.com	JDoe@thermi.com	91%
First@thermi.com	John@thermi.com	3%
FMiddleLast@thermi.com	JMichaelDoe@thermi.com	3%
First.Last@thermi.com	John.Doe@thermi.com	3%

Frequently Asked Questions

Where is Thermi's headquarters located?

Thermi's main headquarters is located at 4719 S Congress Ave Austin, Texas 78745 US. The company has employees across 5 continents, including North AmericaEuropeSouth America.

What is Thermi's phone number?

You can contact Thermi's main corporate office by phone at

+1-214-279-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Thermi's stock symbol?

Thermi is a publicly traded company; the company's stock symbol is ENDO.

What is Thermi's official website and social media links?

Thermi's official website is thermi.com and has social profiles on LinkedIn.

How much revenue does Thermi generate?

As of November 2024, Thermi's annual revenue reached $15M.

What is Thermi's SIC code NAICS code?

Thermi's SIC code is 3089 - Plastics Products, Not Elsewhere Classified NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Thermi have currently?

As of November 2024, Thermi has approximately 51 employees across 5 continents, including North AmericaEuropeSouth America. Key team members include President, Co-Founder: K. O.Owner: P. K.President: T. P.. Explore Thermi's employee directory with LeadIQ.

What industry does Thermi belong to?

Thermi operates in the Medical Equipment Manufacturing industry.

What technology does Thermi use?

Thermi's tech stack includes MySQLCart FunctionalityShopifyWooCommercejQuery UIjQueryOpen GraphVimeo.

What is Thermi's email format?

Thermi's email format typically follows the pattern of . Find more Thermi email formats with LeadIQ.

When was Thermi founded?

Thermi was founded in 2012.

Thermi

Medical Equipment ManufacturingTexas, United States51-200 Employees

Thermi is a global leader in advanced temperature-controlled radiofrequency technology. Thermi systems offer versatile modalities and safely deliver rapid results through controlled heating using RF to impact positive tissue change and naturally stimulate collagen. Clinicians use Thermi technology to help address common signs of aging and/or weight loss, which may include fine lines, post-baby body, cellulite, loose skin and tissue laxity, and empower people to take control over their skin, body and life.

For more information, please visit www.thermi.com